Trial Profile
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs LY 2623091 (Primary) ; Eplerenone
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Feb 2017 Results (n=294) assessing population pharmacokinetics of LY-2623091 using patients data from this and other four trials (NCT01427972, NCT02194465, NCT02242981), published in the Journal of Clinical Pharmacology
- 28 Apr 2014 New trial record